SC 51089 free base
Based on 2 publication(s) in Google Scholar
SC 51089 free base is a selective antagonist of prostaglandin E2 EP1 receptor, with Kis of 1.3, 11.2, 17.5, and 61.1 μM for EP1, TP, EP3, and FP receptors, respectively. SC 51089 free base exhibits neuroprotective activity.
For research use only. We do not sell to patients.
- Purity: 98.60%
- CAS No.: 146033-03-6
- Formula: C22H19ClN4O3
- Molecular Weight:422.86
-
Storage:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications Citing Use of MedChemExpress (MCE) SC 51089 free base
More
Biological Activity
|
EP1 1.3 μM (Ki) |
TP 11.2 μM (Ki) |
EP3 17.5 μM (Ki) |
FP 61.1 μM (Ki) |
SC 51089 free base (5 μM; 24 h) attenuates prostaglandin E2 (PGE2)-induced the death of neuronal cells exposed to t-BuOOH[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:R6/1 mouse model of Huntington's disease (HD), from 13 to 18 weeks of age[3]
-
Dosage:40 μg/kg/day
-
Administration:Infused i.p. at a rate of 0.11 μL/h during 28 days by osmotic mini-pump system
-
Result:Ameliorated motor coordination and balance dysfunction.
Rescued long-term memory deficit.
Improved the expression of specific synaptic markers.
Reduced the number of huntingtin nuclear inclusions in the striatum and hippocampus.
Chemical Information
-
CAS No. 146033-03-6
-
Appearance Solid
-
Molecular Weight 422.86
-
Formula C22H19ClN4O3
-
Color Off-white to light yellow
-
SMILES
O=C(N1C2=CC(Cl)=CC=C2OC3=CC=CC=C3C1)NNC(CCC4=CC=NC=C4)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
-
PLoS One
Impact of Bone Morphogenetic Protein 7 and Prostaglandin receptors on osteoblast healing and organization of collagen. [Abstract]2024 May 16;19(5):e0303202. PMID: 38753641
Solvent & Solubility
DMSO : 25 mg/mL (59.12 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.91 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (279 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Abramovitz M, et, al. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. [Content Brief]
[2]. Saleem S, et, al. Effects of EP1 receptor on cerebral blood flow in the middle cerebral artery occlusion model of stroke in mice. J Neurosci Res. 2007 Aug 15;85(11):2433-40. [Content Brief]
[3]. Anglada-Huguet M, et, al. Prostaglandin E2 EP1 receptor antagonist improves motor deficits and rescues memory decline in R6/1 mouse model of Huntington's disease. Mol Neurobiol. 2014 Apr;49(2):784-95. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3648 mL | 11.8242 mL | 23.6485 mL | 59.1212 mL |
| 5 mM | 0.4730 mL | 2.3648 mL | 4.7297 mL | 11.8242 mL | |
| 10 mM | 0.2365 mL | 1.1824 mL | 2.3648 mL | 5.9121 mL | |
| 15 mM | 0.1577 mL | 0.7883 mL | 1.5766 mL | 3.9414 mL | |
| 20 mM | 0.1182 mL | 0.5912 mL | 1.1824 mL | 2.9561 mL | |
| 25 mM | 0.0946 mL | 0.4730 mL | 0.9459 mL | 2.3648 mL | |
| 30 mM | 0.0788 mL | 0.3941 mL | 0.7883 mL | 1.9707 mL | |
| 40 mM | 0.0591 mL | 0.2956 mL | 0.5912 mL | 1.4780 mL | |
| 50 mM | 0.0473 mL | 0.2365 mL | 0.4730 mL | 1.1824 mL |